Cardioverter defibrillator (CD) is a small device that’s placed in the chest or abdomen or outside. It generates electrical pulses or shocks to help control life-threatening arrhythmias, especially those that can cause sudden cardiac arrest (SCA). SCA is a condition in which the heart abruptly stops beating. If the heart stops beating, blood stops flowing to the brain and other vital organs. SCA usually causes death if it’s not treated within minutes. Thus, the adoption of cardioverter defibrillators is increasing in the high-risk patients with rising incidence & prevalence of various cardiovascular diseases across the globe. “Meticulous Research” in its latest publication states that, the “global market for cardioverter defibrillator devices market is expected to grow at a CAGR of 4.6% from 2017 to 2022 to reach $12,520.0 million by 2022.”
This growth is primarily driven by the increasing incidence & prevalence of cardiovascular diseases with rising graying population, various technological advancements, excessive consumption of alcohol & caffeinated products, and increasing burden of associated diseases such as hypertension, diabetes etc.
Browse in-depth Report on https://www.meticulousresearch.com/product/cardioverter-defibrillator-devices-market-2022/
Cardiovascular disease (CVD), which includes coronary heart, cerebrovascular, and peripheral vascular disease, is the leading cause of death globally; and especially in the U.S. and other developed countries, it is accounting for about 50% of all deaths. The major risk factors include obesity and its consequences such as dyslipidemia, hypertension, insulin resistance leading to diabetes, and cigarette smoking. According to the American Heart Association (AHA), heart disease remains the leading cause of mortality in the U.S., responsible for about one of every three deaths. Stroke accounts for 6% to 7% of all deaths, so overall cardiovascular disease remains responsible for about 40% of all the U.S. deaths. However, there have been alarming trends in the health status of the U.S. teenagers, among whom there are troubling increase in the prevalence of cigarette smoking, obesity, and decreased participation in physical activity programs.
Cardiovascular disease is also a major cause of morbidity and mortality worldwide, especially in developing countries. According to the National Institutes of Health, between 1990 and 2020, the proportion of developing countries in worldwide deaths from cardiovascular disease is projected to increase from 28.9% to 36.3%. The projected increase in the cardiovascular diseases worldwide is mainly due to two trends in developing countries: (1) the eradication of malnutrition and infectious diseases as primary causes of death, which is allowing for an aging of the population, and (2) marked increases in cigarette smoking. According to the projection by the RTI International, the prevalence of cardiovascular diseases (CVD) including hypertension, coronary heart disease, congestive heart failure (CHF), stroke, atrial fibrillation, and all other CVDs was more than 100 million (41.5% of the U.S. population) in 2015. This prevalence is projected to reach more than 130 million people (41.5% of the U.S. population) by 2035. In addition, real total direct medical costs and real indirect costs (due to lost productivity) associated with CVDs were USD 318 billion and USD 237 billion in 2015 respectively; the same are respectively projected to reach USD 749 billion and USD 368 billion by 2035. According to World Health Organization (WHO), an estimated 17.7 million people died from CVDs globally in 2015, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. Over three quarters of CVD deaths take place in low- and middle-income countries and out of the 17 million premature deaths (under the age of 70) due to non-communicable diseases in 2015, 82% are in low- and middle-income countries, and 37% are caused by CVDs.
According to the AHA, Cardiovascular diseases claim more lives each year than all forms of cancer and chronic lower respiratory disease combined. About 92.1 million American adults are living with some form of cardiovascular disease or the after-effects of stroke. Direct and indirect costs of cardiovascular diseases and stroke are estimated to total more than $316 billion; that includes both health expenditures and lost productivity.
Thus, the enormous increase in burden of cardiovascular diseases among those in middle and older age groups across the globe, the alarming trends in cardiovascular risk profiles of young people, and rising CVD related deaths, disability, & DALYs propels the adoption of cardioverter defibrillator devices.
The report provides meticulous analysis of cardioverter defibrillator devices market on the basis of product type [implantable cardioverter defibrillator (transvenous cardioverter defibrillator, subcutaneous cardioverter defibrillator), external cardioverter defibrillator (manual external defibrillator, automated external defibrillator, wearable external defibrillator)], end-user (hospitals, ambulatory surgical center and others), and geography.
The key players analyzed in the Cardioverter Defibrillator Devices Market are Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), LivaNova PLC (U.K.), Stryker Corporation (U.S.), Koninklijke Philips N.V. (Netherlands), Cardiac Science corporation (U.S.), Zoll medical corporation (U.S.), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co. (Japan), and Schiller AG (Switzerland).
Key Topics Covered in This Report:
- Research Methodology
- Executive Summary
- Market Share Analysis
- Market Insights
- Global Cardioverter Defibrillator Devices Market, By Products
- Global Cardioverter Defibrillator Devices Market, By End User
- Geographic Analysis
- Competitive Landscape
- Company Profiles
Don’t miss out on business opportunities in Cardioverter Defibrillator Devices Market – Global Opportunity Analysis And Industry Forecast (2017-2022)